Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2017

21.04.2017 | Laboratory Investigation

CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression

verfasst von: Yiming Ding, Shuqing Yu, Zhaoshi Bao, Yanwei Liu, Tingyu Liang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The malignant transformation of astrocytoma may result from the accumulation of multiple genetic alterations. Current research shows that diffuse astrocytoma (AIIs, WHO grade II) is inherently predisposed to recur locally, and to spontaneously progress to anaplastic astrocytoma (AAIIIs, WHO grade III) and eventually secondary glioblastoma (sGBMIVs, WHO grade IV). The aim of the study was to identify and validate the important gene(s) associated with malignant progression and poor prognosis of astrocytoma. Average expression levels of 82 samples (35 AIIs, 13 AAIIIs and 34 sGBMIVs) were compared to each other through no-paired student test. Candidate genes were screened by DAVID and Kaplan–Meier survival analysis. Further, the significant candidate genes were validated through real-time PCR(qPCR), western blot and immunohistochemistry (IHC) in different grades of glioma. Finally, the association of target gene and clinical molecular characterization was analyzed by Chi-squared analysis. The cell-division cycle protein 20(CDC20, p = 0.0129) and the polo-like kinase 1(PLK1, p = 0.0046) were screened by statistical and Kaplan–Meier survival analysis. The expression levels of CDC20 and PLK1 rose significantly through real-time PCR(qPCR), western blot and IHC. A chi-squared analysis showed that patients with CDC20 high-expression differ from patients with CDC20 low-expression in terms of WHO classification (p < 0.0001), karnofsky performance score (KPS, p < 0.0001), isocitrate dehydrogenase mutation (IDH1, p < 0.0001), phosphatase and tensin homolog mutation (PTEN, p = 0.027) and epidermal growth factor receptor protein amplification (EGFR, p = 0.048). Moreover, the biological processes analyses indicate CDC20 might have an essential role in astrocyte cell proliferation. We demonstrated that the expression level of CDC20 increases significantly along with malignant progression and poor prognosis of astrocytoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Floris H. Hendrikus J. Cathleen R et al (2011) MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 101:405–417CrossRef Floris H. Hendrikus J. Cathleen R et al (2011) MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 101:405–417CrossRef
3.
Zurück zum Zitat Haque A, Banik NL, Ray SK et al (2011) Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci 98:187–234CrossRefPubMedPubMedCentral Haque A, Banik NL, Ray SK et al (2011) Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci 98:187–234CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Liu Y, Hu H, Jiang T et al (2014) Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget 5(24):12593–12606CrossRefPubMedPubMedCentral Liu Y, Hu H, Jiang T et al (2014) Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget 5(24):12593–12606CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57CrossRef Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57CrossRef
6.
Zurück zum Zitat Chang DZ, Ma Y, Ji B, Liu Y et al (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15CrossRefPubMedPubMedCentral Chang DZ, Ma Y, Ji B, Liu Y et al (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Yu H (2007) Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell 27(1):3–16CrossRefPubMed Yu H (2007) Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell 27(1):3–16CrossRefPubMed
9.
Zurück zum Zitat Fry AM, Yamano H (2008) Under arrest in mitosis: Cdc20 dies twice. Nat Cell Biol 10:1385–1387CrossRefPubMed Fry AM, Yamano H (2008) Under arrest in mitosis: Cdc20 dies twice. Nat Cell Biol 10:1385–1387CrossRefPubMed
10.
Zurück zum Zitat Ding Z-Y, Wu H-R, Zhang J-M et al (2014) Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol 7(2):722–727PubMedPubMedCentral Ding Z-Y, Wu H-R, Zhang J-M et al (2014) Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol 7(2):722–727PubMedPubMedCentral
11.
Zurück zum Zitat Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15CrossRefPubMedPubMedCentral Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M (2012) Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 106(4):423–430CrossRefPubMed Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M (2012) Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 106(4):423–430CrossRefPubMed
13.
Zurück zum Zitat Bie L, Zhao G, Cheng P, Rondeau G, Porwollik S, Ju Y, Xia XQ, McClelland M (2011) The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. PLoS ONE 6(10):e25631CrossRefPubMedPubMedCentral Bie L, Zhao G, Cheng P, Rondeau G, Porwollik S, Ju Y, Xia XQ, McClelland M (2011) The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. PLoS ONE 6(10):e25631CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S (2007) Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28(1):81–92CrossRefPubMed Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S (2007) Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28(1):81–92CrossRefPubMed
17.
Zurück zum Zitat Marucci G, Morandi L, Magrini E et al (2008) Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 453:599–609CrossRefPubMed Marucci G, Morandi L, Magrini E et al (2008) Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 453:599–609CrossRefPubMed
18.
Zurück zum Zitat Sunkel CE, Glover DM (1988) Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 89(Pt 1):25–38PubMed Sunkel CE, Glover DM (1988) Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 89(Pt 1):25–38PubMed
20.
Zurück zum Zitat Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9(8):643–660CrossRefPubMed Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9(8):643–660CrossRefPubMed
21.
Zurück zum Zitat Tandle AT et al (2013) Inhibition of PLK1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitization. Eur J Cancer 49(14):3020–3028CrossRefPubMedPubMedCentral Tandle AT et al (2013) Inhibition of PLK1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitization. Eur J Cancer 49(14):3020–3028CrossRefPubMedPubMedCentral
Metadaten
Titel
CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression
verfasst von
Yiming Ding
Shuqing Yu
Zhaoshi Bao
Yanwei Liu
Tingyu Liang
Publikationsdatum
21.04.2017
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2434-8

Weitere Artikel der Ausgabe 1/2017

Journal of Neuro-Oncology 1/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.